The device, Sedasys, is used to mildly sedate patients in preparation for routine medical tests. The sedative’s label requires that it be administered by an anesthesiologist. Despite endorsement by a panel of advisers, the FDA rejected the device.
Upon its rejection of Sedasys, the FDA asked Johnson & Johnson for more data involving anesthesiologists in the control group. Johnson & Johnson responded that the FDA never brought up the idea of including anesthesiologists in the control group prior to the rejection.
The rejection has only heightened criticism of the FDA’s regulatory and approval process. The process has come under fire in recent months from device makers who say it places unnecessary burdens on manufacturers.
Read the Wall Street Journal report on Johnson & Johnson and the FDA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
